SCHEMBL4046024

SCHEMBL4046024

N#Cc1ccc(-n2nc(Nc3ccc4c(c3)OCO4)nc2N)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 8/20 0.56
IRAK4 Q9NWZ3 3/20 0.56
KIT P10721 5/20 0.51
AURKA O14965 2/20 0.51
ULK1 O75385 3/20 0.44
BACE1 P56817 2/20 0.42
AXL P30530 1/20 0.42
CLK1 P49759 1/20 0.40
CLK2 P49760 1/20 0.40
DYRK1A Q13627 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
DYRK1B Q9Y463 1/20 0.40
JAK2 O60674 1/20 0.40
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40
LMNA P02545 1/20 0.40
STK17B O94768 1/20 0.39
STK17A Q9UEE5 1/20 0.39
CDK4 P11802 1/20 0.38
CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4042074 0.85 FLT3 (0.62) FLT3IRAK4KITAURKAULK1
SCHEMBL4042334 0.85 ULK1 (0.47) FLT3IRAK4KITAURKAULK1
SCHEMBL4042371 0.82 ULK1 (0.54) FLT3IRAK4KITAURKAULK1
SCHEMBL2089408 0.81 IDO1 (0.50) FLT3IRAK4KITAURKAULK1
SCHEMBL4044007 0.80 FLT3 (0.62) FLT3IRAK4KITAURKAAXL
SCHEMBL4037968 0.79 FLT3 (0.62) FLT3IRAK4KITAURKAJAK2
SCHEMBL12845571 0.78 LMNA (0.45) FLT3IRAK4KITAURKAULK1
SCHEMBL6224723 0.78 ULK1 (0.44) FLT3IRAK4KITAURKAULK1
SCHEMBL4036162 0.78 FLT3 (0.72) FLT3IRAK4KITAURKABACE1
SCHEMBL12780376 0.77 FLT3 (0.43) FLT3IRAK4KITAURKAULK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 FLT3 220/4885IRAK4 566/4885KIT 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.